Cytek Biosciences Shares Fall After Borealis News and Sales Exit
Cytek Biosciences shares fell 3.8% to $4.05 Wednesday after announcing a 7-laser cell-analysis system debuting at CYTO 2026 and the upcoming exit of senior VP Philippe Busque. Q1 revenue rose 6% to $44.1 million, but net loss widened to $18.9 million. The company kept its 2026 revenue outlook unchanged. About 706,600 shares traded, with a market cap near $521 million.